Chamber and committees

The Scottish Government continues to closely monitor the outcomes of further research to ensure that any decisions to make Evusheld ® available to patients in Scotland in the future are based on the best available evidence. The RAPID C-19 group is a collaborative UK-wide partnership between the National Institute for Health and Care Excellence (NICE), the Scottish Medicines Consortium (SMC) and others. To date, the RAPID C-19 group and the COVID-19 UK expert panel have both considered a full range of evidence, including clinical trial data, in vitro (in the laboratory) analysis and observational studies and have advised that there is insufficient evidence available at this time to support the procurement and deployment of Evusheld ® .

The RAPID C-19 group is keeping this position under active review, including through monitoring any emerging data. Building on the work of the RAPID C-19 group, the SMC is exploring the potential for collaboration with NICE on a single technology assessment (STA) of tixagevimab–cilgavimab (Evusheld ® ) for the prevention of COVID-19. In order to gain further evidence, consideration is also being given to establishing a clinical trial as a route to answering outstanding questions on the link between in vitro tests and clinical outcomes for current and future variants, which is currently not known. The trial may also assist with evaluating the effectiveness and safety of a higher dose of 600mg, which is now being used in a number of countries, which have previously purchased Evusheld®, as this was not tested in the company’s randomised controlled trials.

I have recently written to the UK Government supporting the establishment of a clinical trial and stating my wish to see individuals in Scotland included.